WO2003063763A3 - Essais a mediation par complement pour des procedes in vivo et in vitro - Google Patents

Essais a mediation par complement pour des procedes in vivo et in vitro Download PDF

Info

Publication number
WO2003063763A3
WO2003063763A3 PCT/US2002/016302 US0216302W WO03063763A3 WO 2003063763 A3 WO2003063763 A3 WO 2003063763A3 US 0216302 W US0216302 W US 0216302W WO 03063763 A3 WO03063763 A3 WO 03063763A3
Authority
WO
WIPO (PCT)
Prior art keywords
vivo
complement mediated
vitro methods
mediated assays
complement
Prior art date
Application number
PCT/US2002/016302
Other languages
English (en)
Other versions
WO2003063763A2 (fr
Inventor
Elliot R Ramberg
Original Assignee
Cygene Inc
Elliot R Ramberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cygene Inc, Elliot R Ramberg filed Critical Cygene Inc
Priority to EP02806678A priority Critical patent/EP1506314A4/fr
Priority to JP2003563459A priority patent/JP2005516198A/ja
Priority to AU2002365902A priority patent/AU2002365902A1/en
Priority to CA002447892A priority patent/CA2447892A1/fr
Publication of WO2003063763A2 publication Critical patent/WO2003063763A2/fr
Publication of WO2003063763A3 publication Critical patent/WO2003063763A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés et des compositions conçus pour détecter des substances cibles à analyser, telles que des protéines et des acides nucléiques, dans de multiples compartiments cellulaires. Des modes de réalisation préférés concernent la mise en oeuvre d'essais à médiation par complément et de traitements à médiation par complément chez l'être humain et l'animal. La présente invention concerne également des procédés et des compositions conçus pour surveiller plusieurs stades de maladie et d'infection.
PCT/US2002/016302 2001-05-22 2002-05-22 Essais a mediation par complement pour des procedes in vivo et in vitro WO2003063763A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02806678A EP1506314A4 (fr) 2001-05-22 2002-05-22 Essais a mediation par complement pour des procedes in vivo et in vitro
JP2003563459A JP2005516198A (ja) 2001-05-22 2002-05-22 ｉｎｖｉｖｏおよびｉｎｖｉｔｒｏでの方法に関する補体媒介性アッセイ
AU2002365902A AU2002365902A1 (en) 2001-05-22 2002-05-22 Complement mediated assays for in vivo and in vitro methods
CA002447892A CA2447892A1 (fr) 2001-05-22 2002-05-22 Essais a mediation par complement pour des procedes in vivo et in vitro

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US29261601P 2001-05-22 2001-05-22
US60/292,616 2001-05-22
US29732101P 2001-06-11 2001-06-11
US60/297,321 2001-06-11
US32402901P 2001-09-21 2001-09-21
US60/324,029 2001-09-21

Publications (2)

Publication Number Publication Date
WO2003063763A2 WO2003063763A2 (fr) 2003-08-07
WO2003063763A3 true WO2003063763A3 (fr) 2004-12-09

Family

ID=27670579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/016302 WO2003063763A2 (fr) 2001-05-22 2002-05-22 Essais a mediation par complement pour des procedes in vivo et in vitro

Country Status (5)

Country Link
EP (1) EP1506314A4 (fr)
JP (1) JP2005516198A (fr)
AU (1) AU2002365902A1 (fr)
CA (1) CA2447892A1 (fr)
WO (1) WO2003063763A2 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056456A2 (fr) * 2000-02-02 2001-08-09 Cygene, Inc. Procedes et compositions permettant de detecter une maladie

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUHL ET AL: "A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTC-labeled anti-carcinoembryonic antigen antibody by a two-step approach", CANCER RESEARCH, vol. 55, no. SUPPL., December 1995 (1995-12-01), pages 5749S - 5755S, XP000872898 *
See also references of EP1506314A4 *

Also Published As

Publication number Publication date
WO2003063763A2 (fr) 2003-08-07
EP1506314A4 (fr) 2005-08-24
AU2002365902A1 (en) 2003-09-02
EP1506314A2 (fr) 2005-02-16
JP2005516198A (ja) 2005-06-02
CA2447892A1 (fr) 2003-08-07

Similar Documents

Publication Publication Date Title
WO2003099771A3 (fr) Derives de diaryle-uree utilises pour le traitement des maladies dependant des proteines kinases
EP1764370A3 (fr) Méthodes de traitement des maladies inflammatoires en utilisant des liants spécifiques de l'angiopoietin-2 humain
EP2182006A3 (fr) Compositions et procédés pour le traitement de maladies liées au système immunitaire
WO2002084250A3 (fr) Procedes de detection par spectrometrie de masse et quantification de proteines cibles specifiques dans des echantillons biologiques complexes
WO2003066661A3 (fr) Anticorps humains du dr4 et utilisations
WO2002036771A3 (fr) Imagerie, diagnostic et traitement de maladie
DE69819124D1 (de) Lyophilisation von kultivierten, menschlichen zellen zur konservierung der rna und dna
ATE353366T1 (de) Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
WO2001056456A3 (fr) Procedes et compositions permettant de detecter une maladie
EP2083018A3 (fr) Compositions et procédés associés à STOP-1
WO2001040313A3 (fr) Proteines immunoregulatrices felines, molecules d'acide nucleique et leurs utilisations
WO2002074812A3 (fr) Anticorps pour la prevention et le traitement contre les maladies associees a des souches d'escherichia coli attachantes et effaçantes(aeec)
WO1999058639A3 (fr) Proteines de structure du virus de la maladie affectant le pancreas des poissons et utilisations de ces dernieres
WO2001045738A3 (fr) Utilisation de proteines de choc thermique
EP1133997A3 (fr) Traitement de maladies immunes par l'inteferon beta
WO2002014361A3 (fr) Acides nucleiques et proteines correspondantes appeles 83p2h3 et catrf2e11 utiles dans le traitement et la detection du cancer
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
WO2003063763A3 (fr) Essais a mediation par complement pour des procedes in vivo et in vitro
WO2001040465A3 (fr) Compositions et procedes de traitement de maladies d'ordre immunologique
EP2088197A3 (fr) Antigènes de Haemophilus influenzae et fragments d'ADN correspondants
EP1921451A3 (fr) Analyses induites par complément pour procédés in vivo et in vitro
WO2004072263A3 (fr) Acide nucleique et proteine correspondante dite 158p1d7, utiles pour le traitement et la detection de cancers de la vessie et autres
WO2004058986A3 (fr) Acides nucleiques, proteines et anticorps btl-ii
ATE403716T1 (de) Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
AU2002342858A1 (en) Human high-affinity antibody fragments for essential proteins of the hepatitis-c virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2447892

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003563459

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002806678

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002806678

Country of ref document: EP